Tous Actualités
Suivre
Abonner Novagali Pharma

Novagali Pharma

Novagali Pharma Announces the Update of its "Document De Base" With the French Securities Market Authority ("Autorité des marchés financiers" - AMF)

Evry, France (ots/PRNewswire)

- Not for Distribution in the United States, Canada or Japan
Novagali Pharma, an emerging ophthalmic pharmaceutical company,
announces that the update of its document de base was filed on
September 12th , 2007 to the Autorité des marchés financiers (AMF).
This update concerns half-yearly IFRS accounts ended on June 30th,
2007. The document de base also announces that the product candidate
Vekacia(R) was filed on July 27, 2007 with the European Agency for
the Evaluation of Medicinal Product (EMEA), for marketing approval
for the treatment of Vernal Keratoconjunctivitis ("VKC").
The document de base, registered on July 18, 2007 under number
I.07-132 and its update are available free of charge from Novagali
Pharma, 1 rue Pierre Fontaine, Bâtiment Genavenir IV, 91000 Evry,
France, on the AMF website (http://www.amf-france.org) and on the
Novagali Pharma website (http://www.novagali.com).
The public attention is drawn to the chapter 4 of the document
de base, entitled << Risk Factors >>.
This press release, the information contained herein, the
registration document and the actualization of the registration
document which is referred to, do not constitute an offer to sell or
a solicitation of an offer to buy or subscribe for shares in Novagali
Pharma in any country. No offer to sell shares in Novagali Pharma has
been made, nor will be made, prior to the official approval by the
Autorité des marchés financiers (AMF) of a prospectus comprising the
registration document, its actualization which is the subject of this
press release, and an offering prospectus which will be submitted to
the AMF at a future date.
Shares of Novagali Pharma may not be sold in the United States of
America (as defined under Regulation S of the U.S. Securities Act of
1933, as amended) without registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended. There
will be no registration of all or part of the offering referred to in
this press release in the United States nor any public offering of
Novagali Pharma securities in the United States. This press release
may not be distributed, either directly or indirectly, in the United
States and does not constitute an offer to sell securities in the
United States.
There is no offer in the United Kingdom. In the United Kingdom,
this information is directed only at investment professionals within
the meaning of Article 19(1) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 of the United Kingdom (the
Order) or persons who fall within Article 49(1) of the Order, or any
other person to whom Novagali Pharma may legally transmit an
invitation or solicitation to invest under the Order.
About Novagali Pharma : http://www.novagali.com
Novagali Pharma is an emerging ophthalmic pharmaceutical company
based in the Génopôle biocluster in Evry (France), that develops
innovative products for all segments of the eye. Thanks to its
proprietary technology platforms Novasorb(R) and Eyeject(R), the
company has developed a broad pipeline of 8 innovative products
addressing main ocular conditions as well as orphan diseases. Most
advanced products include Vekacia(R), an orphan product for treatment
of vernal keratoconjunctivitis, Cationorm(R), a CE mark product for
dry eye relief, and Nova22007, a product for the treatment of
moderate-to-severe dry eye syndrome. Founded in 2000, Novagali Pharma
has raised a total amount of Euro 44 million in 3 series of
financing.

Contact:

Press contacts: Novagali Pharma, Geneviève Garrigos,
+33-1-69-87-40-20, +33-6-65-54-60-19,
genevieve.garrigos@novagali.com; Euro RSCG, Estelle Griffe,
+33-1-58-47-95-25, +33-6-23-75-09-23, estelle.griffe@eurorscg.fr

Plus de actualités: Novagali Pharma
Plus de actualités: Novagali Pharma